Zoic Capital
Zoic Capital is a venture capital firm established in 2017, located in Bellevue, Washington, with an additional office in Tampa, Florida. The firm specializes in early-stage investments focused on healthcare innovations that lie at the intersection of life sciences and medical technology. Zoic Capital seeks to identify promising scientific advancements that offer broad intellectual property potential and commercial readiness. The firm invests in technologies that support both the development of medical products and the delivery of care. By combining qualitative insights with quantitative analysis, Zoic Capital aims to make informed investment decisions. Additionally, it employs a milestone-based investment approach, crafting unique deal structures tailored to each portfolio company to foster ongoing momentum and success. With a commitment to mentoring, Zoic Capital leverages its expertise and network to help transform research into impactful, market-ready products.
Trio Labs
Series A in 2024
Trio Labs is a digital manufacturing technology company based in Durham, North Carolina, specializing in high-volume precision metal and ceramic 3D printing. Founded in 2015, the company focuses on transforming the manufacturing of precision parts by eliminating tooling costs and enhancing the throughput of established production processes. This innovative technology allows engineers to achieve the precision of traditional systems while producing metals and ceramics at increased speeds and affordability compared to conventional manufacturing methods.
ProbiusDx
Series B in 2023
ProbiusDx Inc. is a manufacturer of portable diagnostic devices that utilize an electronic sensing platform to analyze multiple target proteins in real time. This technology allows healthcare professionals to detect and monitor blood concentrations, facilitating timely and appropriate therapy for patients requiring critical care in clinical settings. Founded in 2015 and based in El Cerrito, California, ProbiusDx aims to enhance diagnostic capabilities and improve patient outcomes through its innovative solutions.
Chromatan
Seed Round in 2023
ChromaTan Inc. specializes in developing continuous countercurrent tangential chromatography (CCTC) technology for the purification of monoclonal antibodies and proteins. The company's innovative platform addresses significant process bottlenecks in therapeutic protein production, offering a cost-effective, column-free, and continuous purification solution. This technology has undergone extensive beta testing with numerous leading biotech firms, demonstrating a 5-15 times increase in throughput while maintaining or improving product quality. Founded in 2007 and headquartered in Lower Gwynedd, Pennsylvania, ChromaTan aims to provide scalable and efficient alternatives to traditional large-scale column chromatography processes, thereby lowering production costs for biotechnology and contract manufacturing companies.
HDT Bio
Seed Round in 2022
HDT Bio is a clinical-stage biotechnology company focused on developing RNA vaccines and therapeutics to combat infectious diseases and cancer. Utilizing its innovative LION formulation technology, the company creates ribonucleic acid-based products that enhance the delivery and stability of nucleic acids through various administration routes. HDT Bio’s offerings include self-amplifying RNA vaccines and innate immune agonist therapeutics, which aim to activate innate immunity, amplify adaptive immune responses, and disrupt tumor tight junctions. The company's mission is to advance immunotherapy technologies in a cost-effective manner, addressing critical healthcare needs in both developed and low- to middle-income countries, particularly in the fight against some of the world's most dangerous infectious diseases.
ProbiusDx
Series A in 2020
ProbiusDx Inc. is a manufacturer of portable diagnostic devices that utilize an electronic sensing platform to analyze multiple target proteins in real time. This technology allows healthcare professionals to detect and monitor blood concentrations, facilitating timely and appropriate therapy for patients requiring critical care in clinical settings. Founded in 2015 and based in El Cerrito, California, ProbiusDx aims to enhance diagnostic capabilities and improve patient outcomes through its innovative solutions.
HDT Bio
Seed Round in 2020
HDT Bio is a clinical-stage biotechnology company focused on developing RNA vaccines and therapeutics to combat infectious diseases and cancer. Utilizing its innovative LION formulation technology, the company creates ribonucleic acid-based products that enhance the delivery and stability of nucleic acids through various administration routes. HDT Bio’s offerings include self-amplifying RNA vaccines and innate immune agonist therapeutics, which aim to activate innate immunity, amplify adaptive immune responses, and disrupt tumor tight junctions. The company's mission is to advance immunotherapy technologies in a cost-effective manner, addressing critical healthcare needs in both developed and low- to middle-income countries, particularly in the fight against some of the world's most dangerous infectious diseases.
BioROSA Technologies
Convertible Note in 2020
BioROSA Technologies Inc. is a Belmont, Massachusetts-based company focused on developing blood tests for Autism Spectrum Disorders (ASD). Founded in 2018, the company aims to establish a biologically-based standard of care for ASD through innovative diagnostic tools. These tools enable clinicians to identify individuals at risk for ASD by utilizing blood-based biomarkers and advanced machine learning techniques. BioROSA’s platform not only enhances early detection and diagnosis but also supports therapeutic developments by facilitating patient stratification and assessing pharmacodynamics in clinical trials. This comprehensive approach equips healthcare professionals with the necessary resources to improve patient outcomes through timely intervention.
ODS Medical
Seed Round in 2020
ODS Medical Inc. is a Montreal-based medical device company founded in 2015, specializing in the design and manufacture of innovative diagnostic tools for cancer detection. The company's flagship product is a Raman spectroscopy system that enables real-time detection of tissue abnormalities across various clinical settings. By combining advanced optical probes with sophisticated software powered by machine learning algorithms, ODS Medical aims to enhance physicians' decision-making capabilities, providing them with tools that offer high sensitivity, specificity, and accuracy. Through its commitment to developing groundbreaking medical technology, ODS Medical seeks to improve patient outcomes and support healthcare professionals in their diagnostic processes.
Juno Diagnostics
Seed Round in 2019
Juno Diagnostics, Inc. is a health technology company based in San Diego, California, that specializes in cell-free DNA-based prenatal testing. Founded in 2017, the company aims to democratize access to genetic information by developing simple, cost-effective devices for point-of-need genetic testing. Juno's technology allows for noninvasive prenatal tests that enhance sample collection and provide high-quality test results without the challenges associated with traditional testing methods, such as high costs, long lead times, and the need for phlebotomy. In addition to prenatal testing, Juno is also involved in developing genetic testing tools and applications in areas such as epigenetics, inherited diseases, and cancer diagnostics.
Optina Diagnostics
Seed Round in 2018
Optina Diagnostics Inc. is a diagnostics company based in Montréal, Canada, founded in 2010. It specializes in the early detection of Alzheimer's disease through innovative hyperspectral imaging technology that examines the retina. By employing non-invasive diagnostic tests, Optina Diagnostics identifies key biomarkers, such as beta-amyloid plaques, which are crucial for assessing patients' health and disease risk. The company's advanced imaging systems also aid in the detection of age-related macular degeneration and ocular diabetic retinopathy, providing physicians with critical information that enables timely and appropriate patient care. Through its focus on retinal features and artificial intelligence, Optina Diagnostics aims to transform the assessment of brain health and address under-diagnosed diseases.
InnoVein
Venture Round in 2018
InnoVein, Inc. is a medical device company founded in 2015 and based in San Carlos, California. The company specializes in developing an implantable valve designed to regulate blood flow in the veins, particularly targeting elderly patients suffering from venous insufficiency disease. With a focus on advancing cardiac and arterial health, InnoVein aims to address critical needs in vascular treatment through its innovative product offerings.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.